Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-08
ICR Author
Gore, Martin
Larkin, James
Marsden,
Turajlic, Samra
Author
Turajlic, S
Litchfield, K
Xu, H
Rosenthal, R
McGranahan, N
Reading, JL
Wong, YNS
Rowan, A
Kanu, N
Al Bakir, M
Chambers, T
Salgado, R
Savas, P
Loi, S
Birkbak, NJ
Sansregret, L
Gore, M
Larkin, J
Quezada, SA
Swanton, C
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Background The focus of tumour-specific antigen analyses has been on single nucleotide variants (SNVs), with the contribution of small insertions and deletions (indels) less well characterised. We investigated whether the frameshift nature of indel mutations, which create novel open reading frames and a large quantity of mutagenic peptides highly distinct from self, might contribute to the immunogenic phenotype.Methods We analysed whole-exome sequencing data from 5777 solid tumours, spanning 19 cancer types from The Cancer Genome Atlas. We compared the proportion and number of indels across the cohort, with a subset of results replicated in two independent datasets. We assessed in-silico tumour-specific neoantigen predictions by mutation type with pan-cancer analysis, together with RNAseq profiling in renal clear cell carcinoma cases (n=392), to compare immune gene expression across patient subgroups. Associations between indel burden and treatment response were assessed across four checkpoint inhibitor datasets.Findings We observed renal cell carcinomas to have the highest proportion (0·12) and number of indel mutations across the pan-cancer cohort (p<2·2 × 10 -16 ), more than double the median proportion of indel mutations in all other cancer types examined. Analysis of tumour-specific neoantigens showed that enrichment of indel mutations for high-affinity binders was three times that of non-synonymous SNV mutations. Furthermore, neoantigens derived from indel mutations were nine times enriched for mutant specific binding, as compared with non-synonymous SNV derived neoantigens. Immune gene expression analysis in the renal clear cell carcinoma cohort showed that the presence of mutant-specific neoantigens was associated with upregulation of antigen presentation genes, which correlated (r=0·78) with T-cell activation as measured by CD8-positive expression. Finally, analysis of checkpoint inhibitor response data revealed frameshift indel count to be significantly associated with checkpoint inhibitor response across three separate melanoma cohorts (p=4·7 × 10 -4 ).Interpretation Renal cell carcinomas have the highest pan-cancer proportion and number of indel mutations. Evidence suggests indels are a highly immunogenic mutational class, which can trigger an increased abundance of neoantigens and greater mutant-binding specificity.Funding Cancer Research UK, UK National Institute for Health Research (NIHR) at the Royal Marsden Hospital National Health Service Foundation Trust, Institute of Cancer Research and University College London Hospitals Biomedical Research Centres, the UK Medical Research Council, the Rosetrees Trust, Novo Nordisk Foundation, the Prostate Cancer Foundation, the Breast Cancer Research Foundation, the European Research Council.
URI
https://repository.icr.ac.uk/handle/internal/1192
DOI
https://doi.org/10.1016/s1470-2045(17)30516-8
Collections
  • Clinical Studies
Subject
CD8-Positive T-Lymphocytes
Humans
Neoplasms
Melanoma
Carcinoma, Renal Cell
Kidney Neoplasms
DNA, Neoplasm
Antigens, Neoplasm
DNA Mutational Analysis
Lymphocyte Activation
Genomics
Up-Regulation
Phenotype
Frameshift Mutation
Genes, cdc
Databases, Genetic
INDEL Mutation
Exome
Research team
Melanoma and Kidney Cancer
Language
eng
Date accepted
2017-06-23
License start date
2017-08
Citation
The Lancet. Oncology, 2017, 18 (8), pp. 1009 - 1021

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.